Patient Cohorting and Infection Control

Seminars in Respiratory and Critical Care Medicine

Volumn 24, Issue 6, 2003, Pages 703-715

  Koch, Christian ^a,b   Frederiksen, Birgitte ^b   Høiby, Niels ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cystic fibrosis; Infection control; Patient cohorting

Indexed keywords

ACHROMOBACTER; BACTERIAL TRANSMISSION; BURKHOLDERIA CEPACIA; CROSS INFECTION; CYSTIC FIBROSIS; HUMAN; INFECTION CONTROL; LOWER RESPIRATORY TRACT INFECTION; MORBIDITY; MYCOBACTERIUM; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; WARD;

EID: 0347812930     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815666     Document Type: Review

References (130)

1. Høiby N, Frederiksen B. Microbiology of cystic fibrosis. In: Hodson ME, Geddes D, eds. Cystic Fibrosis. London: Arnold; 2000:83-108
2. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002;17:47-56
3. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001;344:11-16
4. Goerke C, Kraning K, Stern M, Döring G, Botzenhart K, Wolz C. Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients. J Infect Dis 2000;181:984-989
5. Branger C, Gardye C, Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiol 1996;45:294-301
6. Di Sant'Agnese PA, Andersen DA. Celiac syndrome: chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas: observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am J Dis Child 1946;72:17-61
7. Høiby N, Friis B, Jensen K, et al. Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatr Scand 1982; suppl 301:33-54
8. Burns DR, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163
9. Givney R, Vickery A, Holliday A, Pegler M, Benn R. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J Hosp Infect 1997;35:27-36
10. Thomas SR, Gyi KM, Gaya H, Hodson ME. Methicillinresistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect 1998;40:203-209
11. Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001;84:160-162
12. Schlichting C, Branger C, Fournier J-M, et al. Typing of Stapbylococcus aureus by pulsed field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J Clin Microbiol 1993;31:227-232
13. Bell SM. Recommendations for control of the spread of methicillin-resistant Staphylococcus aureus infection based on 18 years' experience in a group of teaching hospitals. Med J Aust 1982;1:472-474
14. Cystic Fibrosis Foundation. Patient Registry 2000 Annual Report. Bethesda, MD: September 2001
15. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454
16. Armstrong DS, Grimwood K, Carlin JB, et al. Lower air-way inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-1204
17. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-452
18. Dakin CL, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002;165:904-910
19. Govan JRW, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992;48:912-930
20. Döring G, Jansen S, Noll J, et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 1996;21:90-100
21. Zimakoff J, Hoiby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect 1983;4:31-40
22. Speert DP, Campbell ME. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect 1987;9:11-21
23. Wolz C, Kiosz G, Ogle JW, et al. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis: use of a DNA probe. Epidemiol Infect 1989;102:205-214
24. Govan JRW, Glass S. The microbiology and therapy of cystic fibrosis lung infections. Rev Med Microbiol 1990;1:19-28
25. Botzenhart K, Döring G. Epidemiology and ecology of Pseudomonas aeruginosa. In: Campa M, Bendinelli M, Friedman H, eds. Pseudomonas aeruginosa as an Opportunistic Pathogen. New York: Plenum; 1993:1-18
26. Döring G, Ulrich M, Müller W, et al. Generation of Pseudomonas aeruginosa aerosols during handwashing from contaminated sink drains, transmission to hands of hospital personnel, and its prevention by use of a new heating device. Zentralbl Hyg Umweltmed 1991;191:494-505
27. Pitchford KC, Corey M, Highsmith AK, et al. Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr 1987;111:212-216
28. Rosenfeld M, Emerson J, Astley S, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998;132:125-131
29. Jensen ET, Giwercman B, Ojeniyi B, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. J Hosp Infect 1997;36:117-122
30. Kelly NM, Fitzgerald MX, Tempany E, O'Boyle C, Falkiner FR, Keane CT. Does Pseudomonas cross-infection occur between cystic-fibrosis patients? Lancet 1982;ii:688-689
31. Thomassen MJ, Demko CA, Doershuk CF, Rood JM. Pseudomonas aeruginosa isolates: comparison of isolates from campers and from sibling pairs with cystic fibrosis. Pediatr Pulmonol 1985;1:40-45
32. Tümmler B, Koopmann U, Grothues D, Weissbrodt H, Steinkamp G, von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol 1991;29:1265-1267
33. Renders NHM, Sijmons MAF, van Belkum A, Overbeek SE, Mouton JW, Verbrugh HA. Exchange of Pseudomonas aeruginosa strains among cystic fibrosis siblings. Res Microbiol 1997;148:447-454
34. Grothues D, Koopmann U, von der Hardt H, Tümmler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988;26:1973-1977
35. Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 1998;26:81-88
36. Ojeniyi B, Petersen US, Høiby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS 1993;101:168-175
37. Ojeniyi B, Frederiksen B, Høiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000;29:177-181
38. Fluge G, Ojeniyi B, Høiby N, et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin Microbiol Infect 2001;7:238-243
39. Speert DP, Campbell ME, Henry DA, et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 2002;166:988-993
40. Römling U, Fiedler B, Bosshammer J, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis 1994;170:1616-1621
41. Martin C, Boyd EF, Quentin R, Massicot P, Selander RK. Enzyme polymorphism in Pseudomonas aeruginosa strains recovered from cystic fibrosis patients in France. Microbiology 1999;145:2587-2594
42. Jones AM, Govan JRW, Doherty CJ, et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001;358:557-558
43. McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet 2001;358:558-560
44. Armstrong DS, Nixon GM, Carzino R, et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166:983-987
45. Cheng K, Smyth RL, Govan JR, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639-642
46. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17:505-516
47. Denton M, Kerr K, Mooney L. Transmission of colistin-reisistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002;34:257-261
48. Høiby N, Pedersen SS. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand 1989;78:395-404
49. Farrell PM, Shen G, Splaingard M, et al. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997;100(5):E21-E29
50. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999;8:159-166
51. Vandamme P, Holmes B, Vancanneyt M, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997;47:1188-1200
52. Coenye T, Schouls LM, Govan JR, Kersters K, Vandamme P. Identification of Burkholderia species and genomovars from cystic fibrosis patients by AFLP fingerprinting. Int J Syst Bacteriol 1999;49:1657-1666
53. Coenye T, LiPuma JJ. Multilocus restriction typing: a novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis. J Infect Dis 2002;185:1454-1462
54. Barker PM, Wood RE, Gilligan PH. Lung infection with Burkholderia gladioli in a child with cystic fibrosis: acute clinical and spirometric deterioration. Pediatr Pulmonol 1997;23:123-125
55. Ledson MJ, Gallagher MJ, Walshaw MJ. Chronic Burkholderia cepacia bronchiectasis in a non-cystic fibrosis individual. Thorax 1998;53:430-433
56. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104:206-210
57. Tablan OC, Martone WJ, Doershuk CF, et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: Risk factors and outcomes. Chest 1987;91:527-532
58. Tomashefski JF, Thomasse MJ, Bruce MC, Goldberg HI, Konstan MW, Stern RC. Pseudomonas cepacia-associated pneumonia in cystic fibrosis. Arch Pathol Lab Med 1988;112:166-172
59. Lewin LO, Byard PJ, Davis PB. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990;43:125-131
60. Nelson JW, Doherty CJ, Brown PH, Greening AP, Kaufmann ME, Govan JRW. Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet 1991;338:1525
61. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33:1469-1475
62. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type. Am J Respir Crit Care Med 2001;164:2102-2106
63. Shaw D, Poxton IR, Govan JRW. Biological activity of Burkholderia (Pseudomonas) cepacia iipopolysaccharide. FEMS Immunol Med Microbiol 1995;11:99-106
64. Burns JL, Jonas M, Chi EY, Clark DK, Berger A, Griffith A. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect Immun 1996;64:4054-4059
65. Fisher MC, LiPuma JJ, Dasen SE, et al. Source of Pseudomonas cepacia-ribotyping of isolates from patients and from the environment. J Pediatr 1993;123:754-757
66. Butler SL, Doherty CJ, Hughes JE, Nelson JW, Govan JR. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol 1995;33:1001-1004
67. Holmes A, Govan J, Goldstein R. Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health? Emerg Infect Dis 1999;4:221-227
68. Mortensen JE, Fisher MC, LiPuma JJ. Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment. Infect Control Hosp Epidemiol 1995;16:30-32
69. Gonzalez CF, Mark GL, Mahenthiralingam E, LiPuma JJ. Isolation of soilborne genomovar III Burkholderia cepacia and lytic phages with inter-genomovar host range. Pediatr Pulmonol 2000;suppl 20:S288-S289
70. Balandreau J, Viallard V, Cournoyer B, Coenye T, Laevens S, Vandamme P. Burkholderia cepacia genomovar III is a common plant-associated bacterium. Appl Environ Microbiol 2001;67:982-985
71. LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002;359:2002-2003
72. Sajjan US, Sun L, Goldstein R, Forstner JF. Cable (Cbi) type 11 pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cb1A major sub-unit pilin gene and novel morphology of the assembled appendage fibers. J Bacteriol 1995;177:1030-1038
73. Sun L, Jiang RZ, Steinbach S, et al. The emergence of a highly transmissible lineage of cb1+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1995;1:661-666
74. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-574
75. Mahenthiralingam E, Simpson DA, Speert DP. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol 1997;35:808-816
76. Holmes A, Nolan R, Taylor R, et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999;179:1197-1205
77. LiPuma JJ, Spilker T, Gill LH, Cambell PW, Liu L, Mahenthiralingam E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001;164:92-96
78. Chen JS, Witzmann KA, Spilker T, Fink RJ, LiPuma JJ. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001;139:643-649
79. Pedersen SS, Jensen T, Pressler T, Hoiby N. Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection? Acta Paediatr Scand 1986;75:840-845
80. Editorial. Pseudomonas cepacia: more than a harmless commensal. Lancet 1992;339:1385-1386
81. Thomassen MJ, Demko CA, Doershuk CF, Stern RC, Klinger JD. Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis 1986;134:669-671
82. Hardy KA, McGowan KL, Fisher MC, Schidlow DV. Pseudomonas cepacia in the hospital setting: lack of transmission between cystic fibrosis patients. J Pediatr 1986;109:51-54
83. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990;336:1094-1096
84. Millar-Jones L, Paull A, Saunders Z, Goodchild MC. Transmission of Pseudomonas cepacia among cystic fibrosis patients. Lancet 1992;340:491
85. Smith DL, Smith EG, Gunnery LB, Stableforth DE. Pseudomonas cepacia infection in cystic fibrosis. Lancet 1992;339:252
86. Govan JR, Brown PH, Maddison J, et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993;342:15-19
87. Pitt TL, Kaufmann ME, Patel PS, Benge LCA, Gaskin S, Livermore DM. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol 1996;44:203-210
88. Govan JRW, Nelson JW. Microbiology of cystic fibrosis lung infections-themes and issues. J R Soc Med 1993b;86(suppl 20):S11-S18
89. Smith DL, Smith EG, Gumery LB, Stableforth DE, Dalla Costa LM, Pitt TL. Epidemiology of Pseudomonas aeruginosa infection in cystic fibrosis and the use of strain genotyping. J Infect 1993;26:325-331
90. Burdge DR, Nakielna EM, Noble MA. Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Infect Control Hosp Epidemiol 1993;14:127-130
91. LiPuma JJ, Marks-Austin KA, Holsclaw DS, Winnie GB, Gilligan PH, Stull TL. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J 1994;13:716-719
92. Pegues DA, Carson LA, Tablan OC, et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. J Pediatr 1994;124:694-702
93. Pegues DA, Schidlow DV, Tablan OC, Carson LA, Clark NC, Jarvis WR. Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis. Arch Pediatr Adolesc Med 1994b;148:805-812
94. Johansen HK, Kovesi TA, Koch C, Corey M, Hoiby N, Levison H. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol 1998;26:89-96
95. Muhdi K, Edenborough FP, Gumery L, et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax 1996;51:374-377
96. Paul ML, Pegler MAM, Benn RAV. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres. J Hosp Infect 1998;38:19-26
97. Webb AK, Govan JR. Burkholderia cepacia: another twist nd a further threat. Thorax 1998;53:333-334
98. Fung SK, Dick H, Devlin H, Tullis E. Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis. Can Infect Dis J 1998;9:177-182
99. Saiman L, MacDonald N, Burns JL, Høiby N, Speert DP, Weber D. Infection control in cystic fibrosis: practical recornmendations for the hospital, clinic, and social settings. Am J Infect Control 2000;28:381-385
100. Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990;11:134-138
101. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11:57-80
102. Sattler C, Mason EJ, Kaplan S. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital. Clin Infect Dis 2000;31:1321-1330
103. Burns JL, Emerson J, Stapp JR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163
104. Demko CA, Stern RC, Doershuk CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol 1998;25:304-308
105. Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000;30:10-15
106. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002;121:1754-1760
107. Karpati F, Malmborg AS, Alfredsson H, Hjelte L, Strandvik B. Bacterial colonization with Xanthomonas maltophilia: a retrospective study in a cystic fibrosis patient population. Infection 1994;22:258-263
108. Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival in patients with cystic fibrosis. Am J Respir Crit Care Med 2002;166:356-361
109. Gladman G, Connor PJ, Williams RF, David TJ. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child 1992;67:192-195
110. Hutchison ML, Bonell EC, Poxton IR, Govan JRW. Endotoxic activity of lipopolysaccharides isolated from emergent potential cystic fibrosis pathogens. FEMS Immunol Med Microbiol 2000;27:73-77
111. Dunne WM Jr, Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin Infect Dis 1995;20:836-841
112. Vu-Thien H, Moissenet D, Valcin M, Dulot C, Tournier G, Garbarg-Chenon A. Molecular epidemiologiy of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Eur J Clin Microbiol Infect Dis 1996;15:876-879
113. Valdezate S, Vindel A, Maiz L, Bequero F, Escobar H, Canton R. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg Infect Dis 2001;7:113-121
114. Krzewinski JW, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol 2001;39:3597-3602
115. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999
116. Fabbri A, Tacchella A, Manno G, Viscoli C, Palmero C, Gargani GF. Emerging microorganisms in cystic fibrosis. Chemioterapia 1987;6:32-37
117. Moissenet D, Baculard A, Valcin M, et al. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin Infect Dis 1997;24:274-275
118. Smith MJ, Efthimiou J, Hodson ME, Batten JC. Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984;39:369-375
119. Kilby JM, Gilligan PH, Yankaskas JR, Highsmith WE, Edwards LJ, Knowles MR. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992;102:70-75
120. Aitken ML, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 1993;103:1096-1099
121. Hjelt K, Højlyng N, Howitz P, et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with cystic fibrosis. Scand J Infect Dis 1994;26:569-576
122. Olivier KN, Yankaskas JR, Knowles MR. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin Respir Infect 1996;11:272-284
123. Olivier K, Handler A, Less JH, Tudor G, Knowles MR. Clinical impact of nontuberculous mycobacteria on the course of cystic fibrosis lung disease. Pediatr Pulmonol Suppl 2000;20:102-103
124. Tomashefski JF Jr, Stern RC, Demko CA, Doershuk CF. Nontuberculous mycobacteria in cystic fibrosis: an autopsy study. Am J Respir Crit Care Med 1996;154:523-528
125. Fauroux B, Delaisi B, Clement A, et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997;16:354-3581
126. Oermann CM, Starke JR, Seilheimer DK. Pulmonary disease caused by Mycobacterium kansasii in a patient with cystic fibrosis. Pediatr Infect Dis J 1997;16:257-259
127. Cullen AR, Cannon CL, Mark EJ, Colin AA. Mycobacterium abscessus infection in cystic fibrosis: colonization or infection? Am J Respir Crit Care Med 2000;161:641-645
128. Oliver A, Maiz L, Canton R, Escobar H, Baquero F, Gomez-Mampaso E. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001;32:1298-1303
129. Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998;52:453-490
130. Bange FC, Brown BA, Smaczny C, Wallace RJ Jr, Bottger EC. Lack of transmission of Mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis 2001;32:1648-1650